PLK2 and neoplasm: Building on the favorable outcomes of this investigation, further exploration will involve examining AJ2 alone, sNK alone, and their combination at varying dose levels to establish the minimal effective, maximum tolerable, and optimal therapeutic values for managing tumor-induced bone loss.